Navigation Links
Medac Pharma, Inc. Announces Multiple Poster Presentations During the 2013 ACR/ARHP Annual Meeting

CHICAGO, Oct. 21, 2013 /PRNewswire/ -- Medac Pharma, Inc., a privately held pharmaceutical company focused on the development of new molecules and improving the effectiveness of existing medicines, announced today that data from two recently completed clinical trials for its lead product will be presented during the 2013 American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) Annual Meeting to be held October 25 – 30, in San Diego, CA at the San Diego Convention Center.

"We're encouraged by the data each of these studies have generated as it provides additional validation for our unique approach to delivering a broad dosing range of methotrexate to patients with rheumatoid arthritis," remarked Terri Shoemaker, President and CEO of Medac Pharma, Inc.  "Our primary goal is to provide this extremely underserved patient population with a more personalized delivery technique to managing their disease, and we believe we're on track for accomplishing that through our unique approach."

The posters will highlight Medac Pharma Inc.'s rationale for the development of its lead product by presenting data on relative bioavailability and ease of self-administration.

Monday, October 28, 2013:Title:Successful Self-Administration of Methotrexate In Rheumatoid Arthritis Patients Using a Prefilled Autoinjector PenTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract #1354Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)Title:Subcutaneous Administration Of Methotrexate With a Prefilled Autoinjector Pen Results In a Higher Relative Bioavailability Compared To Oral Administration Of MethotrexateTime:Available: 9:00 a.m. PT – 11:00 a.m. PTPoster:Abstract # 1355Location:Exhibit Hall B2-C-D (8:30 a.m. PT – 4:00 p.m. PT)About Medac Pharma, Inc.Medac Pharma, Inc. is the wholly owned subsidiary of medac GmbH, a well known and respected global pharmaceutical company that has been making scientific and therapeutic discoveries for more than 40 years.

Medac Pharma Inc. is focused on developing therapies with the potential to make meaningful differences in patients' lives.  The company's approach is to improve existing agents by enhancing the mode of delivery, addressing safety profiles and inventing ways to maximize efficacy.

For more information, please visit

For Media:
Tiberend Strategic Advisors, Inc.
Andrew Mielach; (212) 375-2694

SOURCE Medac Pharma, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Pre-Market Analysis: MannKind, Galena Biopharma, Ariad Pharma, and Novavax
2. Todays Research: Delcath Systems, Astex Pharma, BioMarin Pharma, and Akorn
3. Stipulation Of Dismissal Of Claims By Plaintiff Cornerstone Biopharma, Inc.
4. Todays Research: Inovio Pharma, Sequenom, Peregrine Pharma, Onyx Pharma, and Optimer Pharma
5. NovoBioPharma, Partnership of Top Life Science Experts, Launches
6. Zosano Pharma, Inc. Appoints Nandan Oza as Chief Operations Officer
7. Zosano Pharma, Inc. Expands Board of Directors with Addition of Kleanthis G. Xanthopoulos, Ph.D.
8. Zosano Pharma, Inc. Announces Key Strategic Hire
9. DFH Pharma, USA Partners with Hetero Group, INDIA to Develop 2nd Generation HIV Maturation Inhibitor Drugs
10. Morning Research on Sequenom, Peregrine Pharma, Onyx Pharma, and Inovio Pharma
11. Todays Research on PDL BioPharma, Dendreon, Medivation, ACADIA Pharma, and Cell Therapeutics
Post Your Comments:
(Date:11/26/2015)... STOCKHOLM , November 26, 2015 ... the potential to use SyMRI to find optimal contrast weighting ... brain tumor metastases, and has signed a research agreement with ... at the hospital. Using SyMRI, it is possible to generate ... parameter settings after the patient has left, thus making it ...
(Date:11/26/2015)... 2015 ) ... "2016 Future Horizons and Growth Strategies in ... Supplier Shares, Country Segment Forecasts, Competitive Intelligence, ... --> ) has announced ... Horizons and Growth Strategies in the French ...
(Date:11/26/2015)... DUBLIN , Nov. 26, 2015 Research ... of the "Advanced Wound Care Market by Type ... Ulcers), End User (In-Patient Facility, Out-Patient Facility), and Geography ... offering. --> --> ... the description, definition and forecast of the global advanced ...
Breaking Medicine Technology:
(Date:11/27/2015)... (PRWEB) , ... November 27, 2015 , ... ... a safe and convenient way to dispense prescription medications at home, so he ... effective way to monitor and dispense prescription medications. In doing so, it could ...
(Date:11/27/2015)... ... , ... MPWH, the No.1 Herpes-only dating community in the world, revealed that over 50% of ... than 3.7 billion people under the age of 50 – or 67% of the population ... global estimates of HSV-1 infection . , "The data shocks us highly!" said Michelle ...
(Date:11/27/2015)... , ... November 27, 2015 , ... ... an innovative online platform for mental health and wellness consultation, has collaborated with ... partnership will bridge the knowledge gap experienced by parents and bring advice from ...
(Date:11/27/2015)... ... 27, 2015 , ... Indosoft Inc., developer and distributor of ... 11 LTS (Long Term Support) into its Q-Suite 5.10 product line. , Making ... with a version of Asterisk that will receive not only security fixes, but ...
(Date:11/26/2015)... ... ... The Catalent Applied Drug Delivery Institute today announced a ... selection in early phase drug development. The first of these is to be ... UK’s emerging life sciences companies, corporate partners, and investors, at Milton Park, Oxford, ...
Breaking Medicine News(10 mins):